FDA adds rare eye condition warning to popular GLP-1 medications

On Nov. 9, the U.S. Food and Drug Administration (FDA) announced it will require manufacturers of GLP-1 medications, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).

The warning follows several studies that identified an association between GLP-1 medications and NAION, although they did not establish that the medications directly cause the condition.

NAION (pronounced NYE-on) is caused by decreased blood flow and oxygen to the optic nerve, resulting in a sudden and painless decrease in vision and sometimes permanent vision loss. It is sometimes called an "eye stroke."

Yin Allison Liu is a neuro-ophthalmologist at the UC Davis Department of Ophthalmology and Vision Science. She has studied NAION and treated patients with the condition.

"NAION remains very rare," Liu said. She notes that with an annual prevalence of 2.3-10.3 people per 100,000 individuals aged 50 and older, there are only about 6,000 new cases per year in the U.S.

Research identifies potential association

A 2024 paper in JAMA Ophthalmology identified a potential association between GLP-1s and NAION. The findings added to growing concerns about a possible link between GLP-1 medications and NAION and contributed to ongoing FDA safety evaluations.

The agency analyzed the incidence of NAION in patients treated with GLP-1s compared with the incidence in patients treated with placebos or a non-GLP-1 glucose-lowering medication.

They found patients treated with GLP-1s had a NAION incidence rate of 6.4 cases per 100,000 person-years (a measure that accounts for both the number of people in a study and how long they were followed) compared to 3.8 events per 100,000 person-years in the placebo and other medications group.

Another FDA study found that the rate of NAION was higher in people taking GLP-1 drugs compared to those taking DPP-4 inhibitors (an oral medication for diabetes). The same study also found the rate of NAION was similar between people taking GLP-1 medications and those taking SGLT-2 inhibitors, another class of diabetes drugs.

Overall health an important factor

Although the FDA findings raise concerns, Liu emphasizes that treatment decisions should consider a person's overall health.

The absolute risk of NAION remains small. For someone with diabetes, obesity or substantial cardiovascular risk, the benefits of treatment may outweigh the potential risk to vision. Patients should not stop their medication simply out of fear. They should discuss their individual risks and benefits with their prescribing clinician."

Yin Allison Liu, neuro-ophthalmologist, UC Davis Department of Ophthalmology and Vision Science

She notes that an important unanswered question is whether the risk changes with treatment duration.

"We do not yet know whether there is a particular period during treatment when NAION is most likely to occur," Liu said. "We hope further FDA analyses and longer-term studies will help clarify that."

Routine eye care visits can check the eyes

The exact cause of NAION is not fully understood, but Liu noted that certain optic nerve features may increase susceptibility. These can be identified through an eye examination, sometimes with additional imaging:

  • A crowded optic disc: A small or absent central depression, called the "cup," leaves nerve fibers tightly packed together. This is often described as a small cup-to-disc ratio or a "disc at risk."
  • Optic disc drusen: Deposits within the optic nerve head that may contribute to crowding.

Liu added that having these features does not mean that a person will develop NAION. She suggests using routine eye care visits to assess optic nerve anatomy, rather than requiring a separate screening appointment for everyone taking GLP-1 medications.

"Routine diabetic eye exams offer an opportunity to look for a crowded optic nerve, or a 'disc at risk,'" she said. "When screening is done through teleophthalmology, sufficiently clear photographs may help estimate the size of the optic nerve's central cup. However, these assessments cannot reliably predict who will develop NAION."

Symptoms of NAION

The main symptom of NAION is a sudden, painless loss of vision, often in one eye.

Anyone who develops sudden vision loss or rapidly worsening vision should seek immediate evaluation by an eye care professional or visit the emergency department. Sudden vision changes are a medical emergency.

Liu also suggests contacting the prescribing clinician promptly to determine whether to stop the GLP-1 medication.

Potential treatments for NAION being investigated

Currently, there is no medical or surgical treatment that reverses vision loss due to NAION.

UC Davis Health is participating in a clinical trial evaluating cenegermin, an investigational nasal spray for people with recent-onset NAION. The treatment is still being studied, and its effectiveness has not yet been established. People interested in learning more about the clinical trial can visit the study page.

"Managing diabetes, cardiovascular risk and other health conditions remains essential," Liu said. "Our recommendations will continue to evolve as the evidence becomes clearer."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Popular diabetes drugs do not alter the risk of developing a blinding eye condition